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Abstract
Recent case-controlled clinical studies show that bronchioalveolar carcinomas (BACs) are
correlated with smoking. Nicotine, the addictive component of cigarettes, accelerates cell
proliferation through nicotinic acetylcholine receptors (nAChRs). In this study, we show that
human BACs produce acetylcholine (ACh) and contain several cholinergic factors including
acetylcholinesterase (AChE), choline acetyltransferase (ChAT), choline transporter 1 (CHT1,
SLC5A7), vesicular acetylcholine transporter (VAChT, SLC18A3) and nACh receptors (AChRs,
CHRNAs). Nicotine increased the production of ACh in human BACs and ACh acts as a growth
factor for these cells. Nicotine-induced ACh production was mediated by α7-, α3β2-, and β3nAChRs, ChAT and VAChT pathways. We observed that nicotine upregulated ChAT and
VAChT. Therefore, we conjectured that VAChT antagonists, such as vesamicol, may suppress
the growth of human BACs. Vesamicol induced potent apoptosis of human BACs
in cell culture and nude mice models. Vesamicol did not have any effect on EGF or IGF-IIinduced growth of human BAC's. siRNA-mediated attenuation of VAChT reversed the apoptotic
activity of vesamicol. We also observed that vesamicol inhibited Akt phosphorylation during cell
death, and overexpression of constitutively active Akt reversed the apoptotic activity of
vesamicol. Taken together, our results suggested that disruption of nicotine-induced cholinergic
signaling by agents such as vesamicol may have applications in BAC therapy.

KEY WORDS: Bronchioalveolar carcinoma, Acetylcholine, α7/3 nAChR, VAChT, CHT1,
Vesamicol, Akt
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Précis
Findings that cholinergic signaling are critical to the survival of bronchioalveolar carcinoma cells
should prompt immediate clinical testing of approved drugs that disrupt this pathway to
determine if they can improve the efficacy of treatments for this form of lung cancer.
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Introduction
Bronchioalveolar carcinoma (BAC) is a subtype of lung adenocarcinoma arising from type II
pneumonocytes in the lung. The World Health Organization (WHO) revised its classification of
BAC’s in 2004 to include lung adenocarcinomas, which grow in a lepidic fashion along the
alveolar septa without invasion into the stroma, pleura, blood vessels or lymphatics (1-3). The
incidence of pure BAC is about 4%; however, mixed subtypes, including BACs with stromal
invasion and pulmonary adenocarcinoma with BAC-like morphological features, account for
almost 20% of all non-small cell lung cancers (NSCLC) (4). Cigarette smoking is the leading risk
factor for the development of lung cancer. It is estimated that smoking is associated with 8090% of lung cancer cases throughout the world (5). Smoking has a stronger association with
small cell lung cancer (SCLC) than with adenocarcinoma (6). BAC is a relatively rare type of
adenocarcinoma; therefore, only a few epidemiological studies have investigated the
relationship between BAC and smoking (7-9).
Traditionally, the role of tobacco smoking in the etiology of human BAC originates from a
series of early studies involving human lung cancer patients, most of which were non-smokers
(1). These non-smoking lung cancer patients had higher incidence of BAC than other types of
lung cancer. The resulting impression was that smoking is unimportant in the etiology of human
BAC (1). However, these reports did not contain any cohort or case control studies that formally
determined the relationship of human BACs to cigarette smoking.
Epidemiological data have demonstrated an association between human BACs and
smoking (7, 8, 10). The risk of developing BACs is greater for people who started smoking at a
younger age, smoked for a longer time or smoked more cigarettes per day. Conversely, the risk
decreases in proportion to the duration of smoking cessation. Smoking habits have been
correlated to both the mucinous and non-mucinous form of human BACs (11). Rolen et al.,
(2003) performed a case-control study and compared smoking status of 198 BAC patients to an
equal number of controls. They observed that the risk of BAC is strongly related to the smoking
4

history of patients. They also found that both current and former smokers were at risk of
developing BAC (9). Recently, Boffeta et al., (2011) analyzed seven case controlled studies in
the USA comprising of 799 cases of BACs and 15,859 controls. They found that ever smokers
are at a two-fold greater risk of developing lung BAC as compared to never smokers. They also
observed a positive correlation between the duration and amount of smoking and the
development of lung BAC (8).
Although cigarette smoke is comprised of a mixture of many compounds, nicotine is the
addictive component of cigarette smoke (12). Several convergent studies have shown that
nicotine promotes the progression of human BACs and confers resistance against
chemotherapy (12, 13). All of these observations suggest that nicotine-induced mitogenic and
pro-survival pathways contribute to the pathophysiology of BACs.
The proliferative activity of nicotine is mediated by nicotinic acetylcholine receptors
(nAChRs) (12). The endogenous ligand for nAChRs is acetylcholine (ACh) (14). Recent studies
have shown that nAChRs are present in non-neuronal tissues, including lung cancer cells, lung
epithelial cells, endothelial cells and keratinocytes (12). Small cell lung cancers (SCLCs) and
squamous cell carcinoma of the lung (SCC-L) express all components of the ACh autocrine
loop, including acetylcholinesterase (AChE), choline acetyltransferase (ChAT), vesicular
acetylcholine transporter (VAChT), choline transporter1 (CHT1), nAChRs and muscarinic
acetylcholine receptors. SCLC and SCC-L cells secrete ACh, which promotes their proliferation
(14-17). Song et al., (2008) found that the muscarinic receptor antagonist Darifenacin displayed
anti-tumor activity in human SCC-L in both cell culture and nude mice models (15, 18). Such
observations suggest that the cholinergic network may be a viable molecular target in the
therapy of human lung cancer.
The present manuscript investigates whether the cholinergic loop exists in human BACs.
We show that human BAC cell lines produce ACh and express cholinergic proteins. We also
show for the first time that nicotine can amplify the components of the cholinergic loop in human
5

BACs. Nicotine increased the production of ACh in human BAC cell lines in a time- and dosedependent manner. ACh acted as a growth factor for human BAC cells. Nicotine upregulated
VAChT and ChAT expression in human BAC cells. We conjectured that nicotine-induced
increase of VAChT levels may provide a viable molecular target in human BACs. The VAChT
antagonist vesamicol induced robust apoptosis of human BAC cells in both cell culture and in
vivo models. Vesamicol did not affect EGF or IGF-II-induced growth pathways in human BACs.
This finding suggests that the pro-apoptotic activity of vesamicol is specific to the acetylcholinesignaling pathway in human BACs. The pro-apoptotic activity of vesamicol was mediated via
suppression of Akt activation. The data presented in this paper characterizes the cholinergic
system in human BACs and offers novel avenues for BAC therapy. The results of our
experiments are relevant to BAC patients who are exposed to secondhand smoke or use
nicotine-based cessation devices (e.g. patches and gums) to quit smoking.

Methods
Ethical use and care of laboratory animals.
Nude mice (Charles River Laboratories International, Inc., Wilmington, MA, USA) were
acclimatized for one week. They were housed in autoclaved cages with ad libitum access to
food and water in HEPA-filtered racks and closely monitored by animal facility staff. All
procedures involving nude mice were conducted according to the Animal Care and Use
Guidelines in a facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International and were approved by the Institutional Animal
Care and Use Committee (IACUC) of the Joan C. Edwards School of Medicine, Marshall
University (Protocol # 421).
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Authentication of Cell lines
The human bronchioalveolar carcinoma (BAC) cell lines, A549, NCI-H358, and NCIH650 (hereinafter referred to as A549, H358 and H650), and the human SCC-L cell line H520
were obtained from ATCC (Manassas, VA). The A549, H358 and H520 cells were authenticated
by the ATCC Cell Authentication Service in October 2012. They used Short Tandem Repeat
(STR) profiling for authentication of these cells, and the results are summarized in
Supplementary Figure S1. The human BAC cell line H650 was passaged for less than six
months and therefore did not require authentication. This cell line was obtained from ATCC
which used STR profiling for its characterization. Primary human pulmonary alveolar epithelial
cells (HPAEpiCs) were obtained from ScienCell (Carlsbad, CA). These cells were characterized
by ScienCell using immunostaining for specific markers. A certificate of analysis was provided.

Cell Culture
A549 and H358 were cultured in RPMI-1640, supplemented with 2.0 mM glutamine, 100
units/mL penicillin, 50.0 µg/mL streptomycin, 1.0 mg/mL BSA, 1X insulin, transferrin, sodium
selenite (ITS) supplement (Invitrogen Corp, Carlsbad, CA), 50 nM hydrocortisone and 1.0 µg/mL
human EGF (15, 16). This medium will be referred to hereafter as serum-free RPMI (SF-RPMI).
For a few experiments, the cells were rendered quiescent by incubating them in SF-RPMI
containing ¼ ITS supplement, 12.5 nM hydrocortisone, 0.25 µg/mL EGF. This media, reduced
serum-free RPMI, will be referred to hereafter as SF-RPMI-R. H650 was grown in a 1:1 mixture
of DMEM and Ham’s F-12K, supplemented with 2.0 mM L-glutamine, 100 units/mL penicillin,
50.0 µg/mL streptomycin, 0.02 mg/mL bovine insulin, 1X ITS, 50 nM hydrocortisone, 100 mM
ethanolamine, 100 mM O-phosphorylethanolamine, 100 mM 3,3`,5-triiodo-L-thyronine, 5% (w/v)
BSA, 0.5 mM sodium pyruvate, 10 mM HEPES, and 100 µg/mL EGF. The culture conditions for
H520 and HPAEpiCs are described in Supplementary Methods.
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Measurement of ACh production
A549 cells were grown in SF-RPMI. On the day of the assay, 100 µM neostigmine (an
acetylcholinesterase inhibitor) was added to each plate (16). Four hours after the addition of
neostigmine, the indicated doses of nicotine were added and the cells were incubated at 37°C
for 36 hours. The supernatant was collected and spun at 800g. Subsequently, the supernatant
was lyophilized, reconstituted with 1/5 volume autoclaved water, and stored at -80°C until
further

analysis.

The

amount

of

ACh

in

the

sample

was

measured

using

the

Choline/acetylcholine Quantification Kit (Biovision, Milpitas, CA, USA) (15-17). Each sample
was assayed in triplicate, and the whole experiment was performed two independent times for
each cell line.

Immunohistochemical staining of VAChT, ChAT in human BAC tissue microarray (TMA)
and normal lung TMA
Human BAC tissue microarray slides (Abnova, Walnut, CA, USA) were deparaffinized
and rehydrated as described previously (19, 20). The immunostaining was performed using
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturer’s
protocol. The dilutions of primary antibodies used were 1:50 (polyclonal VAChT antibody) and
1:25 (monoclonal ChAT antibody). The images were captured by phase contrast microscopy
(Leica Microsystems, Wetzlar, Germany) at a magnification of 400X. The normal lung TMA (US
Biomax Inc, Rockville, MD) was stained for VAChT and ChAT as described above.

VAChT, ChAT and nAChR ELISA assays
The concentration of VAChT and ChAT was measured using the VAChT ELISA Kit
(Antibodies Online Inc., Atlanta, GA, USA) and the ChAT ELISA Kit (NovaTein Biosciences,
Cambridge, MA), according to manufacturer’s instructions. The expression of nAChR subunits
in human BAC cell lines was analyzed by using 7-, 3-, β2- and β3- nAChR ELISA Kits
8

(Antibodies Online Inc.). Each of these assays was completed in duplicate, and the whole
experiment was performed two independent times for each cell line.

TUNEL assays
A549 or H358 cells (10,000 cells/well) were seeded into an 8-well chamber slide in SFRPMI and incubated overnight at 37°C (13, 19). Subsequently, the medium was replaced with
SF-RPMI-R for 24 hours. After 24 hours, cells were treated with 100 nM nicotine in the presence
or absence of 50 M vesamicol. Cells were incubated for 48 hours at 37°C. Apoptosis was
measured by the colorimetric TUNEL Assay (Promega Corporation, Madison, WI, USA),
according to manufacturer’s protocol. The magnitude of TUNEL-positive cells in the untreated
control wells were considered to be equal to 1, and the TUNEL-positive cells in the remaining
wells were calculated as fold-increase relative to the control. The experiment was performed
two independent times with two replicates in each experiment.

Caspase-3 activity assay
Human BAC cells were incubated in SF-RPMI-R for 24 hours. Subsequently, cells were
treated with 100 nM nicotine in the presence or absence of 50 M vesamicol for 48 hours at
37°C. Lysates were made using the Caspase-3 Activity Kit (EMD Millipore Corporation, Billerica,
MA, USA). Caspase-3 activity in untreated lysates was considered to be equal to 1, and the
activity observed in treated lysates was calculated as fold-increase relative to the control cells.
The experiment was performed two independent times with two replicates in each experiment.

Antitumor studies in nude mice
Four week-old male nude mice were acclimatized for one week and housed in
autoclaved cages with ad libitum access to food and water in HEPA-filtered racks. A549 cells
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were re-suspended in a 1:1 (v/v) solution of serum-free media and Matrigel matrix (BD
Biosciences, San Jose, CA). One million cells were injected subcutaneously between the
scapulae of each mouse (15, 21). After the tumors reached approximately 100 mm3, the mice
were randomized into two groups, a control (N=8) and a treatment (N=8) group. The control
group was fed an AIN-76A based diet containing 10% corn oil. The treatment group was fed a
diet containing 50 mg vesamicol/kg food, (approximately 10 mg vesamicol/kg body weight) per
day. Both groups were administered nicotine in their drinking water (200 g/mL in 2% saccharin
sodium) (20, 21). The drug treatment was continued until tumors of the control group reached
approximately 1500 mm3. Mice were weighed once per week. Their food consumption and
water consumption was monitored daily. Tumor lengths (l), widths (w) and height (h) were
measured daily (6 days a week) for each mouse. Tumor volumes were calculated as (l x w x
h)/2 (22, 23). After euthanizing the mice, the tumors were excised. Half of the tumor was snap
frozen in liquid nitrogen. Tumor lysates were prepared using T-Per lysis buffer (Pierce
Biotechnology, Rockford, IL), according to manufacturer’s protocol (24). The other half of the
tumor was fixed in 10% formalin buffered saline and used for immunohistochemistry.

Statistical analysis
All data was plotted using GraphPad Prism 5 Software, Inc (La Jolla, CA, USA), and was
represented as the mean ± standard error of the mean (SEM). Results from the control and
treated samples were compared using an analysis of variance followed by a Neumann-Keuls
multiple comparison test. All analyses were completed using a 95% confidence interval. Data
was considered significant when p < 0.05.
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Results
Cholinergic proteins are expressed on bronchioalveolar carcinomas.
The cholinergic pathway proteins have been traditionally found in neuromuscular
junctions and in neuronal cells (14). However, studies have shown that genes for these proteins
are found in SCC-L and SCLC cells (14). ELISA experiments were performed to examine
whether cholinergic proteins were expressed in human BAC cell lines and in HPAEpiCs. Figure
1A shows that multiple nAChR subunits are expressed on A549, H358 and H650 human BAC
cells. Similarly, HPAEpiCs also expressed a diverse array of nAChR subunits. Immunoblotting
experiments were performed to examine the presence of AChE, ChAT, CHT1 and VAChT
(Figure 1B) in human BAC cell lines and in HPAEpiCs. H520 human SCC-L cells were used as
the positive control for both of the experiments. We observed that human BAC cell lines, as well
HPAEpiCs normal lung cells, express VAChT, ChAT, AChE and CHT1.

The antibodies to

VAChT, ChAT, CHT1 and AChE were found to be specific and showed only a single band at the
correct molecular weight in full screen western blots (Supplementary Figure S2A-D). The
expression of ChAT and VAChT was examined in human BAC tumors isolated from patients
using BAC tissue microarray (TMA). The specific VAChT and ChAT antibodies described above
were used for the immunostaining. Each TMA contained eighty-one samples of human BAC
tumors from patients. Human BAC tumors displayed robust expression of both ChAT (Figure
1C; left panel) and VAChT (Figure 1D; right panel). Both VAChT and ChAT were found to be
expressed in the cytoplasm. This observation is in agreement with previous data from several
research groups showing that VAChT and ChAT are localized in the cytoplasm of cells (25-28).
We also analyzed the expression of VAChT and ChAT in normal lung tissues using normal lung
TMA (Supplementary Figure S3A-B).

This TMA contained 20 samples of normal lung tissue.

We found that normal lung tissues also express VAChT and ChAT, and these proteins are
localized in the cytoplasm.
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Nicotine induces acetylcholine production in bronchioalveolar carcinomas.
Next we wanted to assess the effect of nicotine on acetylcholine production in human
BACs. We observed that nicotine increased ACh production from A549 cells in a concentrationdependent manner (Figure 2A). The maximum ACh production (2 M) was observed at 100 nM
nicotine and remained constant thereafter. A similar pattern was observed in H358 and H650
human BAC cells (Figure 2A). We also performed a time-kinetics experiment with nicotine on
A549 cells and found that the maximal ACh production (2 M) occurred at 36 hours and
remained relatively constant thereafter (Figure 2B). Therefore, we selected a concentration of
100 nM nicotine and a 36 hour time point for all of our ACh production experiments. A point to
note here is that 100 nM nicotine is within the concentration range found in the plasma of an
average smoker (1 nM - 1 M) (29).
Studies by Song et al., (2003) have demonstrated that ACh acts as an autocrine growth
factor for SCLC cells (16, 17). We analyzed the mitogenic activity of ACh in human A549 BAC
cells and found that ACh stimulated the proliferation of A549 cells in a concentration-dependent
manner; the maximal proliferation observed at 2 M ACh (Figure 2C: white bars). This finding is
significant because the maximal mitogenic activity of ACh is similar to the amount of ACh
secreted by human BACs. We repeated the BrdU cell proliferation assays in H358 human BAC
cells and obtained similar results (Figure 2C: black bars). Our observations raise the possibility
that nicotine induces the production of ACh in human BACs, which in turn, promotes the growth
of human BACs in an autocrine manner.
Next, we wanted to determine the role of nAChRs in nicotine-induced ACh production.
The treatment of A549 cells with the generalized nAChR antagonist mecamylamine (MCA)
suppressed nicotinic-induced ACh production, whereas atropine, an antagonist to the closely
related muscarinic receptor, had little to no effect on nicotine-induced ACh levels. We obtained
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similar results in another human BAC cell line H358. Our results show that nicotine promotes
ACh levels in human BACs in an nAChR dependent manner (Supplementary Figure S4A).
The next series of experiments aimed to investigate which specific nAChR subunits were
responsible for nicotine-induced ACh production. Our data showed that the treatment of A549
and H358 human BAC cells with 7-nAChR subunit antagonists, methyllycaconitine (MLA) and
-bungarotoxin (-BT), ablated nicotine-induced ACh production. Additionally, 1 μM of conotoxin MII (-CT; 3β2 and β3 subunit antagonist) reversed the pro-secretory effect of
nicotine, whereas DHβE (3β2 and 4β2 nAChR antagonist) had little to no effect
(Supplementary Figure S4B). Taken together, these results suggest that nicotine-induced ACh
secretion is mediated via nAChRs, specifically through the 7-, 3β2- and β3-containing-nAChR
subunits.
Finally, we wanted to examine the effect of choline/acetylcholine transporters on
nicotine-induced ACh production. The treatment of A549 and H358 cells with hemicholinium (an
antagonist of CHT1) suppressed nicotine-induced ACh secretion. Similarly, vesamicol (an
antagonist of VAChT) potently abrogated nicotine-induced ACh production (Supplementary
Figure S4C). Taken together, this shows that CHT1 and VAChT function are vital for nicotineinduced ACh production.

Nicotine increases VAChT and ChAT levels in human BAC cells.
We wanted to investigate whether nicotine promoted ACh secretion via the
VAChT/ChAT pathway in BAC cells. We used an ELISA kit to measure VAChT and ChAT
levels, which allowed us to quantitate these levels in an accurate and sensitive manner. We
observed that the VAChT ELISA kit detected VAChT levels in asynchronous A549, H358, H650
BAC cells and HPAEpic normal lung cells (Supplementary Figure S5). The relative pattern of
VAChT expression in the ELISA correlated well with the results obtained from western blotting
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(Figure 1B; fourth panel). ELISA The treatment of A549 cells with 100 nM nicotine caused a 4fold increase in VAChT levels (Figure 3A) and a 1.5-fold increases in ChAT levels (Figure 3B).
Similarly, nicotine increased VAChT levels in H358 by 5.5-fold and ChAT levels by 1.4-fold
(Figure 3A and 3B). We also tested the effect of nicotine on AChE and CHT1 in human BACs.
We found that nicotine decreased AChE levels in H358 and A549 human BACs (Figure 3C).
The levels of CHT1 were relatively unaffected by nicotine in both the cell lines (Figure 3C).

The VAChT antagonist vesamicol causes apoptosis in human BACs.
Our results showed that nicotine-induced ACh production was blocked by the VAChT
inhibitor vesamicol (Supplementary Figure S4C). It may be envisaged that vesamicol will
suppress nicotine-induced ACh production and thereby block ACh-induced growth of human
BACs. Additionally, we conjectured that nicotine-induced upregulation of VAChT should provide
a viable molecular target for vesamicol therapy in human BACs. MTT assays (Supplementary
Methods online) demonstrated that vesamicol decreased the viability of nicotine-treated A549
and H358 human BAC lines in a concentration-dependent manner. The maximum reduction in
cell viability was observed at 50 M vesamicol (Figure 4A). Therefore, we used 50 M
vesamicol for all further experiments.
Next, we wanted to examine whether vesamicol induced apoptosis in human BAC cell
lines. Quiescent A549 and H358 cells were treated with 100 nM nicotine in the presence or
absence of 50 M vesamicol. Apoptosis was measured by TUNEL assays. Figure 4B shows
that vesamicol caused robust apoptosis in both A549 and H358 human BACs. The results of the
TUNEL assays were verified by caspase-3 activity assay. We observed that vesamicol caused
2.5- to 3-fold increase in apoptosis relative to nicotine-treated human BAC cells (Figure 4C).
We also wanted to assess the effect of vesamicol on other mitogenic signaling pathways
in human BACs (30-35). Several convergent studies indicate that EGF and IGF-II are potent
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growth factors for human BAC cells (30-35). We performed a BrdU assay (Supplementary
Methods online) to test the effect of vesamicol on EGF-induced proliferation of human BAC cell
lines. We found that vesamicol has no effect on EGF-induced proliferation of A549 and H358
human BAC cell lines (Figure 4D).

Similarly, vesamicol did not affect IGF-II-induced

proliferation of human A549 and H358 cells (Figure 4E). Our findings seem to suggest that
vesamicol specifically inhibits the acetylcholine-proliferative pathway in human BACs.

Vesamicol induces apoptosis in human BAC cells by specifically targeting VAChT
Vesamicol is a well characterized antagonist of VAChT (36). However, previous studies
indicate that vesamicol also binds to the sigma-receptor in several types of human cancer cells
(37, 38). We wanted to examine whether vesamicol induced apoptosis in human BAC cells by
specifically targeting VAChT. For this purpose, we used siRNA methodology to suppress the
expression of VAChT or sigma receptor in A549 cells. A549 cells were transfected with VAChTsiRNA or sigma-receptor-siRNA (Supplementary Methods Online). Eighteen hours post
transfection, the cells were rendered quiescent by incubating them in SF-RPMI-R medium for 24
hours (19). Subsequently, the cells were treated with 100nM nicotine in the presence or
absence of 50 M vesamicol for 48 hours at 37°C. A549 cells transfected with a non-targeting
control-siRNA was used as the negative control for the experiment. After 48 hours cell lysates
were made and vesamicol-induced apoptosis was measured by the caspase-3 activity assay.
We observed that vesamicol-induced apoptosis was decreased upon transfection of
VAChT-siRNA and unaffected by sigma-receptor-siRNA. The apoptotic activity of vesamicol
was also unaffected by the control non-targeting siRNA (Figure 5A). We repeated these
experiments in H358 human BAC cells and obtained similar results (Figure 5B). These
experiments were also repeated with a second independent VAChT-siRNA (Ambion Inc., Grand
Island, NY) and similar results were obtained (Figure 5C and D).
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Parallel transfection experiments were performed to test the efficacy of

VAChT-siRNA

and sigma-receptor-siRNA in A549 cells. ELISA assays show that the levels of VAChT are
robustly suppressed upon transfection with both sets of VAChT-siRNA (Supplementary Figure
S6A and S6B) in A549 and H358 human BAC cells. Western blotting experiments show that the
levels of sigma receptor are ablated upon transfection of sigma-receptor-siRNA (Supplementary
Figure S6C and S6D) in both A549 and H358 cells.
We also examined whether vesamicol was targeting the VAChT pathway at
concentrations lower than 50µM. We chose 10µM and 25µM vesamicol for our experiments.
Caspase-3 activity assays show that the cellular apoptosis induced by 10µM vesamicol was
suppressed by two independent sets of VAChT-siRNA in both A549 and H358 cells
(Supplementary Figure S7A and S7B). Similarly, the transfection of VAChT-siRNA efficiently
abrogated the apoptotic activity of 25µM vesamicol in nicotine-treated A549 and H358 cells
(Supplementary Figure S7C and S7D). ELISA assays indicate that both the VAChT-siRNA
decreased the expression of VAChT in A549 and H358 cells (Supplementary Figure S7E).
Taken together, our data show that vesamicol caused apoptosis in human BAC cells by
specifically targeting the VAChT pathway.
Vesamicol-induced apoptosis is mediated by the Akt pathway in human BACs.
The Akt signaling pathway plays a vital role in nAChR signaling in normal lung cells and
lung cancer cells (12). We observed that the treatment of A549 and H358 human BAC cells with
nicotine and vesamicol caused potent decreases in phosphorylated-Akt levels (Figure 6A and
B). The levels of both phosphorylated-Akt (Thr308) and phosphorylated-Akt (Ser473) are
robustly suppressed upon vesamicol treatment, whereas total Akt levels remain constant
(Figure 6A and 6B, respectively). Western blotting analysis also showed that vesamicol had little
to no effect on the expression of phosphorylated-Akt in untreated A549 (or H358) cells (Figure
6C and 6D). The transfection of constitutively active Akt (pcDNA3-HA-Akt-CA; Supplementary
16

Methods Online) reversed the apoptotic effect of vesamicol, demonstrating that vesamicol
induces cell death by suppressing Akt activation (Figure 6E and 6F). Western blotting analysis
confirms the over expression of HA-tagged Akt in A549 and H358 human BAC lines upon
transfection (Supplementary Fig. S8A and S8B).

Vesamicol inhibited the growth of human A549 cells in vivo.
The anti-tumor activity of vesamicol was examined in vivo using a nude mice model (15,
21). A549 human BAC cells were injected between the scapulae of nude mice. The tumors were
allowed to grow until approximately 100 mm3, after which they were randomized into two
groups. The control group was administered nicotine in the drinking water. The “vesamicol
group” was administered 50 mg vesamicol/kg food along with nicotine. Our results showed that
the administration of vesamicol decreased the tumor growth rate of A549 human BAC tumors
(Figure 7A). The administration of 50 mg vesamicol/kg food in the diet was well tolerated and
caused no discomfort or weight loss in mice (mean control = 25.6 ± 0.6 g; mean vesamicol
treated = 25.2 ± 0.5 g). Additionally, food intake (mean control = 6.2 ± 0.04 g/day; mean
vesamicol-treated = 6.2 ± 0.04 g/day) and water consumption (mean control = 11.0 ± 0.4
mL/day; mean vesamicol-treated = 11.2 ± 0.3 mL/day) was similar between groups.
H and E staining of the tumors revealed the presence of apoptotic bodies in the tumors
belonging to the vesamicol-treated mice (Figure 7B). Caspase-3 activity assays indicate that
tumor lysates from vesamicol-treated mice displayed about 2.5-fold greater apoptosis relative to
control nicotine-treated mice (Figure 7C). Our data from cell culture suggested that vesamicol
induced apoptosis by suppression of Akt activation. We wanted to investigate whether
vesamicol-treated tumors had lower levels of phosphorylated-Akt. Western blotting analysis
revealed that vesamicol-treated tumors had substantially lower levels of phosphorylated-Akt
(Thr308 and Ser 473) relative to nicotine-treated A549 tumors (Figure 7D; top two panels). The
total Akt levels were similar in all four pairs of tumors (Figure 7D; third panel from the top).
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Taken together, these data indicate that vesamicol decreases tumor growth rates of A549
human BAC tumors in vivo by inducing robust apoptosis via an Akt-dependent pathway.

Discussion
Our study shows for the first time that human BACs produce ACh and contain a
functional acetylcholine-signaling system. A functional cholinergic loop has also been detected
in SCLCs, SCC-Ls and normal bronchial epithelial cells (14). Most importantly, nicotine
regulates the cholinergic machinery and increases ACh levels by about 10-fold in human BACs.
Nicotine upregulates the levels of cholinergic proteins, namely VAChT and ChAT, and
concomitantly downregulates AChE in human BACs. Nicotine-induced increases of VAChT and
ChAT promote ACh content and its transport into the extracellular environment. On the other
hand, nicotine decreases AChE levels, which in turn suppress ACh degradation. Thus, the
enhanced levels of ACh provide proliferative stimuli to human BACs. The amplification of the
cholinergic network by nicotine offers novel therapeutic strategies for BAC therapy. These
phenomena are highly significant since about 30% of lung cancer patients continue to smoke,
use nicotine-based cessation patches or gum, or are exposed to environmental tobacco smoke
after their diagnosis (39-41).
We observed that nicotine caused a 3-fold increase in VAChT and ChAT levels in
human BAC cells. This led us to hypothesize that antagonists of VAChT should attenuate
nicotine-induced ACh production and thereby suppress the growth of human BACs. As a “proofof-principle” we decided to use the well-characterized VAChT antagonist, vesamicol, for our
experiments. Our hypothesis was supported by the results of Song et al., (2003) who showed
that vesamicol suppressed the growth of H82 human SCLC cells in vitro. We believe that our
results are the first to report characterizing the anti-cancer activity of VAChT antagonists in
human BAC using both cell culture and in vivo model systems. We found that vesamicol
induced robust apoptosis in human BAC cells in both cell culture and in vivo systems.
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A survey of literature shows that only very few studies have evaluated the anti-tumor
activity of vesamicol. Ogawa et al., (2009) evaluated radioiodinated vesamicol analogs for tumor
imaging and anti-tumor activity (42, 43). They found that radioiodinated-vesamicol-analogs
suppressed the growth of human prostate cancer cells in mice model. However, their results
showed that vesamicol exerted its anti-tumor activity by binding to the sigma receptor on DU145
prostate cancer cells (42). Several convergent studies have shown that vesamicol is also a
ligand for the sigma-receptor. However, our experiments involving VAChT-siRNA and sigmareceptor-siRNA showed that the anti-cancer activity of vesamicol was specifically mediated by
VAChT. It is possible that sigma-receptors do not play a vital role in nicotine-induced
proliferative signaling in human BAC cells.
The present manuscript shows that apoptotic effects of vesamicol are mediated via
suppression of the Akt pathway. Clinical studies have shown that the activation of Akt is highly
prevalent in human BAC tumors. Nicotine causes rapid activation of Akt and its downstream
substrates. Studies by West et al., (2001) have speculated that inhibition of the Akt pathway
may be a viable strategy for treatment of tobacco-related lung cancers (44, 45). The EGFR
inhibitors Gefitinib and Erlotinib have been shown to suppress Akt phosphorylation in human
lung cancer cells (46, 47). Similarly, PI-3kinase/Akt inhibitors, i.e. LY294002 and deregulin,
suppress proliferation of human BAC cells in vitro and in mouse models of tobacco
carcinogenesis (48). Our results suggest that VAChT-antagonists such as vesamicol are
another class of therapeutic agents capable of inhibiting activated Akt in human BACs.
The acetylcholine-signaling pathway has been found to regulate multiple cellular
functions, such as proliferation, cell-to-cell contact, differentiation and cytoskeletal integrity (14).
Apart from lung cancer cells, endothelial cells, mesothelial cells, immune cells and keratinocytes
have been found to synthesize, transport and degrade acetylcholine (14). The pharmacological
manipulation of this non-neuronal cholinergic system by agents, such as vesamicol, could lead
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to the development of novel therapies for multiple tobacco-related diseases including lung
cancer.
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Figure 1. Human BACs and normal human alveolar epithelial cells (HPAEpiCs) express
cholinergic proteins. (A) ELISA assays show that human BAC cell lines and HPAEpiCs express
multiple nAChR subunits. The assay was completed in duplicate, and the whole experiment was
performed two independent times. Results indicated by a different letter are significantly
different (P < 0.05). (B) HPAEpiCs and human BACs express AChE, ChAT, CHT1 and VAChT.
H520 human SCC-L cells were used as the positive control for the experiments outlined in (A)
and (B). GAPDH was used as the loading control, and the results were quantitated by
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densitometric analysis. The experiment was repeated twice, and the representative data is
shown. (C) and (D) Immunohistochemistry of the human BAC microarray showed that BAC
tumors (isolated from patients) express ChAT and VAChT in the cytoplasm, adjacent to the
hemotoxylin-counterstained dark nuclei in the tissue samples. A tumor microarray containing 81
cores of human BACs was used for these experiments and four panels of representative photos
are shown. Scale bar = 20 µm.
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Figure 2. Nicotine induces the production of the growth factor ACh in human BACs. (A) Nicotine
caused a concentration-dependent increase in ACh production in A549, H358 and H650 human
BAC cell lines. (B) Time kinetics of nicotine-induced ACh production in A549 human BAC cells.
The maximal ACh production was observed at 100 nM nicotine at 36 hours. (C) ACh stimulated
proliferation of A549 and H358 cells. BrdU assays show that 2 µM of ACh (which is
approximately the amount of ACh produced in nicotine-treated BAC cells) caused a 4- to 4.5fold increase in proliferation of A549 and H358 human BACs. Each sample was analyzed in
triplicate. Data represent mean + SEM from two independent experiments. Results indicated by
a different letter are significantly different (P < 0.05).
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Figure 3. Effect of nicotine on cholinergic proteins in human BACs. (A) The treatment of A549
and H358 cells with 100 nM nicotine caused 4- to 5-fold increase in VAChT levels. (B) Nicotine
produces a modest increase in ChAT levels. (C) Nicotine decreases AChE levels in both A549
and H358 cells. The levels of CHT1 are relatively unaffected by nicotine in human BAC cells.
Data represent mean + SEM from two independent experiments. Each sample was analyzed in
triplicate. Results indicated by a different letter are significantly different (P < 0.05).
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Figure 4. Vesamicol caused apoptosis in human BAC cells. (A) MTT assays showed that
vesamicol decreases the viability of A549 and H358 cells in a concentration-dependent manner.
Each sample was analyzed in triplicate. (B) The treatment of human BAC cell lines with 50 µM
vesamicol caused 2.5- to 3-fold apoptosis in nicotine-treated A549 and H358 cells. (C) The
apoptotic activity of vesamicol was confirmed with caspase-3 activity assay and similar results
were obtained. (D) Vesamicol had no effect on EGF-induced proliferation of A549 and H358
cells. BrdU assays show that the treatment of A549 and H358 human BAC cells with 10 ng/ml
EGF causes robust proliferation. The addition of 50 µM vesamicol along with EGF produced no
effect on EGF-induced proliferation of human BACs.

(E) BrdU assays demonstrate that

vesamicol does not suppress IGF-II-induced proliferation of human BAC cell lines.
sample was analyzed in duplicate.

Each

Data represent mean + SEM from two independent

experiments. Results indicated by a different letter are significantly different (P < 0.05).
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Figure 5. Vesamicol-induced apoptosis is specifically mediated by VAChT in human BAC cells.
(A) Caspase-3 activity assays showed that the transfection of VAChT-siRNA reversed
vesamicol-induced apoptosis in nicotine-treated A549 cells, whereas transfection of sigmareceptor-siRNA (SigmaR-siRNA) or control-siRNA has no effect. (B) The experiment was
repeated in H358 human BAC cells, and similar results were obtained. (C) The suppression of
VAChT, with another independent VAChT-siRNA (VAChT-siRNA-2), abrogated vesamicolinduced apoptosis in A549 human BAC cells. (D) The experiment was repeated in H358 cells,
33

and similar results were obtained. Each sample was analyzed in duplicate. Data represent
mean + SEM from two independent experiments. Results indicated by a different letter are
significantly different (P < 0.05).
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Figure 6. The apoptotic activity of vesamicol is mediated by the Akt pathway. (A) The treatment
of A549 and H358 human BAC cells with nicotine and vesamicol inhibited Akt phosphorylation
at Thr-308. (B) Vesamicol decreased the levels of phospho-Akt (Ser-473) in nicotine-treated
A549 and H358 cells. (C) Vesamicol had no effect on the levels of phospho-Akt (Thr-308) in
untreated A549 and H358 cells. (D) The treatment of quiescent A549 and H358 cells 50 µM
vesamicol does not affect phospho-Akt (Ser-473) levels. (E) The transfection of pcDNA3-HAAkt-CA (T308D, S473D) reverses the apoptotic activity of vesamicol, whereas transfection of
the empty vector had no effect on vesamicol-induced apoptosis in A549 human BAC cells. (F)
The transfection experiment was repeated in H358 cells and similar results were obtained. Data
represent mean + SEM from two independent experiments. Each sample was analyzed in
duplicate. Results indicated by a different letter are significantly different (P < 0.05).
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Figure 7. Vesamicol induces apoptosis of human BAC tumors in vivo. (A) The administration of
vesamicol (50 mg vesamicol/kg food) decreased the growth rate of A549 human BAC tumors
xenografted in nude mice. The nude mice experiments comprised of eight mice per group. (B)
The tumors from the mice were excised and stained with H & E. The black arrow shows the
presence of apoptotic bodies in the tissue sections. The vesamicol-treated tumors (right panel)
37

showed a greater number of apoptotic bodies relative to the mice administered vehicle (left
panel). Scale bar = 500 µm. (C) An aliquot of the tumors from nude mice were frozen and
lysates were made. Caspase-3 activity of these lysates was measured. The vesamicol-treated
tumors had higher caspase-3 activity (indicating higher apoptosis) than the tumors in the control
group. (D) Western blotting analysis showed that vesamicol-treated tumors showed lower levels
of phospho-Akt (Thr308) and phospho-Akt (Ser473). The western blot was quantitated using
NIH ImageJ 1.46p. Data represent mean + SEM. Results indicated by a different letter or an
asterisk are significantly different (P < 0.05).
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Supplementary Methods
Reagents, Antibodies and Constructs
Nicotine, α-bungarotoxin (α-BT, α7-nAChR antagonist), dihydro-β-erythroidine
hydrobromide (DHβE, α4β4- and α4β2-nAChR antagonist), hemicholinium (ChAT
antagonist) and EGF were purchased from Sigma-Aldrich (St. Louis, MO). Acetylcholine
(ACh)

chloride,

atropine

(generalized

muscarinic

antagonist),

mecamylamine

hydrochloride (MCA, generalized nAChR antagonist), α-conotoxin MII (α-CT, α3β2- and
β3-nAChR antagonist), methyllycaconitine citrate (MLA, α7-nAChR antagonist), and (±)vesamicol hydrochloride (VAChT antagonist) were purchased from Tocris (Ellisville,
MO). Human IGF-II was obtained from Millipore, Temecula, CA.
VAChT, AChE polyclonal antibodies and human sigma receptor monoclonal antibody
were obtained from Santa Cruz Biotechnology, Santa Cruz, CA. CHT1 polyclonal and ChAT
monoclonal antibodies were obtained from Millipore Inc. Phospho-Akt (Thr308), Phospho Akt
(Ser473) and total Akt polyclonal antibodies were obtained from Cell Signaling Inc (Danvers,
MA). HA monoclonal antibody was purchased from Covance (Princeton, NJ). The secondary
donkey-anti-rabbit, rabbit-anti-mouse antibodies were obtained from Thermo Scientific,
Rockford, IL.

The plasmid pcDNA3-HA-Akt-CA (T308D, S473D) (Addgene plasmid 142571)
was a kind gift from Dr. Jim Woodgett, University of Ontario.

Cell lines and Cell Culture
The human squamous cell carcinoma of the lung (SCC-L) cell line NCI-H520 (hereafter
referred to as H520) was obtained from American Type Culture Collection (Rockville, MD).
H520 cells were grown in RPMI-1640 medium (Mediatech, Inc, Manassas, VA) supplemented
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with 2 mM glutamine, 100 U/mL penicillin, 50 μg/mL streptomycin, and 10% FBS. The cells
were incubated at 37°C in 5% CO2. The H520 cells were authenticated by the ATCC Cell
Authentication service in October 2012. They used Short Tandem Repeat (STR) profiling, for
authentication of these cells and the results are summarized in Supplementary Figure 1.
Primary human pulmonary alveolar epithelial cells (HPAEpiCs) were obtained from
ScienCell (Carlsbad, CA) and cultured in alveolar epithelial cell medium (AEpiCM)
supplemented with 5% FBS. All experiments with the HPAEpiCs were performed between
passage numbers 3-7. HPAEpiCs were characterized by ScienCell Inc. by immunostaining for
specific markers. A certificate of analysis was provided.

Lysates and Western Blotting
Lysates for each cell line were made using the NP-40-based lysis protocol (1, 2). Cells
were harvested and washed three times with ice cold 1X PBS. Cells were then lysed with M2
lysis buffer (20 mM Tris, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 4 µM
DTT, 5 mM PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 25 µg/ml leupeptin, 5
µg/ml pepstatin, 5 µg/ml aprotinin, 25 µg/ml trypsin-chymotrypsin inhibitor). Seventy five
microliters of lysis buffer was added for every 20 µL of packed cell volume. The lysate was
rotated at 4oC for 30 minutes and subsequently spun at 15000g for 15 minutes at 4oC. The
supernatant was collected for further analysis. The protein concentration of the lysate was
measured using a Bradford Reagent (Bio-Rad Labs, Hercules, CA, USA). Two hundred
microgram aliquot of the protein was run on a 10% SDS-PAGE gel and transferred onto
nitrocellulose membranes (Bio-Rad Labs).
The relative expression of the indicated proteins was analyzed by western blotting. The
signal obtained in the western blot experiments was detected by the SuperSignal West Dura
Extended Duration Substrate (Pierce Biotechnologies, Rockford, IL, USA). The results of the
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western blotting assays were quantitated by ImageJ 1.46p (National Institutes of Health,
Bethesda, MD, USA).

BrdU Proliferation Assays
BrdU assays were used to examine the proliferative effects of ACh on A549 or H358
cells (3, 4). A549 cells were plated in 8-well chamber slide at a density of 10,000 cells/well in
SF-RPMI. After overnight incubation, the medium was aspirated and replaced with SF-RPMI
containing ¼ growth factors (referred to hereinafter as SF-RPMI-R) for 24-hours. After 24-hours,
these cells were treated with varying concentrations of ACh, and incubated for 48-hours at
37°C. The rate of BrdU incorporation in cells was measured by the BrdU Labeling and Detection
Kit II (Roche Applied Science, Indianapolis, IN, USA) according to manufacturer’s instructions.
The magnitude of BrdU incorporation in control cells was considered to be equal to 1, and the
BrdU incorporation observed in ACh-treated cells was calculated as fold-increase relative to the
control cells. The assay was completed in duplicate, and the whole experiment was performed
two independent times.
BrdU assays were also performed to examine the effect on vesamicol on EGF-induced
proliferation as well as IGFII-induced proliferation in human BAC cells. A549 cells were seeded
in 8-well chamber slides as described above. Subsequently the cells were rendered quiescent in
serum-free RPMI for 24-hours. After 24-hours, cells were treated with 10ng/ml EGF (or 20ng/ml
IGF-II) in the presence or absence of 50 µM vesamicol for 36-hours at 37°C. The concentrations
of EGF and IGF-II were selected from previous publications. The BrdU assay was performed as
described above.

MTT Assay

41

A549 or H358 cells were plated in 96-well plates at a density of 2500 cells/well in SFRPMI. After overnight incubation at 37oC, the medium was replaced with SF-RPMI-R. Cells
were treated with 100 nM nicotine in the presence or absence of varying concentrations of
vesamicol for 48-hours. After 48-hours, the MTT assay was performed as described previously
(1, 4). The experiment was performed two independent times with three replicates in each
experiment for each cell line.

siRNA Transfection Assays
Chemically synthesized, double stranded VAChT-siRNA and Sigma receptor-siRNA
(sigmaR-siRNA) were purchased from Santa Cruz Biotechnologies, Inc. The transfection
experiments were performed in A549 and H358 cells. The transfection of 75 nM VAChT-siRNA
or control-siRNA was performed by using Oligofectamine reagent (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s protocol (1, 2). Eighteen hours post-transfection, the
cells were incubated in SF-RPMI-R media for 24 hours, after they were treated with 100 nM
nicotine in the presence or absence of 50 µM vesamicol for 48 hours. The effect of VAChTsiRNA or Sigma-R-siRNA on the apoptotic activity of vesamicol was measured by the caspase3 activity kit (Millipore). A non-targeting siRNA sequence (Santa Cruz Biotechnologies, Inc.) was
used as a control for the transfection experiments (5, 6) (1). The entire experiment was
repeated with a second VAChT-siRNA (Ambion, Grand Island, NY, USA). Each transfection was
performed in duplicate, and the entire assay was performed 2 independent times.
The efficiency of VAChT-siRNA transfection was assessed by the VAChT ELISA kit
(Antibodies Online) in A549 and H358 cells. Western blotting experiments were performed to
examine the expression of the Sigma-receptor after siRNA transfection (1). The results of the
western blotting assays were quantitated by ImageJ 1.46p (National Institutes of Health,
Bethesda, MD, USA).
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Transient Transfection Assays
A549 or H358 cells were cultured to 50-70% confluence in SF-RPMI medium and
transfected with 4 µg of pcDNA3-Akt-constitutively active (pcDNA3-HA-Akt-CA) using Fugene
HD transfection reagent (Roche Applied Sciences, Indianapolis, IN), according to the
manufacturer’s protocols (2, 5). Cells transfected with the empty vector pcDNA3 were used as a
control (mock transfected). After overnight incubation, the cells were rendered quiescent by
incubating them in SF-RPMI-R medium for 24 hours. Subsequently, the cells were treated with
100 nM nicotine in the presence or absence of 50 M vesamicol for 48 hours at 37°C. Lysates
were made and the apoptotic activity of vesamicol was measured by the caspase-3 activity kit
(EMD Millipore Corporation). The experiment was performed two independent times with two
replicates in each experiment. The over-expression of the plasmid after transfection was
analyzed by western blotting. The results of the western blotting assays were quantitated by
ImageJ 1.46p (National Institutes of Health, Bethesda, MD, USA).
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Figure S1. A summary of the cell line authentication data for A549, H520 and H358 cells was
obtained from the ATCC Cell Line Authentication service. They used Short Tandem Repeat
(STR) profiling, for authentication of these cells. As indicated in the last row, the profile of the
cell lines used in this study were a 100% match for A549, NCI-H520 and NCI-H358 profile
described in the ATCC database.
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Figure S2. Full screen western blots (corresponding to Figure 1B) for the cholinergic proteins
namely ChAT, VAChT, AChE and CHT1 in normal human pulmonary alveolar epithelial cells
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(HPAEpiCs) and human BAC cell lines. The human SCC-L cell line H520 was used as the
positive control for the immunoblotting experiments.
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Figure S3. Normal lung tissues contain ChAT and VAChT. Immunohistochemical staining of
normal lung TMA reveals the presence of ChAT and VAChT on normal lung tissues isolated
from patients. The normal lung tissue microarray (TMA) was stained with ChAT monoclonal
antibody and VAChT polyclonal antibody, used in the western blotting experiments outlined in
Figure S2. The slides were counterstained with hemotoxylin. The staining of both ChAT and
VAChT was observed to be cytoplasmic, adjacent to the hemotoxylin-stained dark nuclei in the
tissue sample. This TMA contained 20 normal lung tissue samples. Photographs of four
representative samples are shown above. Scale bar = 20µm
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Figure S4. Nicotine-induced ACh production is mediated by 7-, 3β2- and β3-containingnAChR subunits and requires VAChT and CHT1. A. Nicotine-induced ACh production was
inhibited by 1 µM of the generalized nAChR antagonist, mecamylamine (MCA), but was
unaffected by 1 µM of the muscarinic receptor antagonist atropine in A549 and H358 cells. The
treatment of A549 and H358 human BACs with MCA or atropine alone had little to no effect on
48

ACh levels. B. The treatment of A549 and H358 human BAC cells with 1 μM of
methyllylcaconitine (MLA), -bungarotoxin (-BT) and -conotoxin (α-CT) MII ablated nicotineinduced ACh production, whereas DHβE (3β2 and 4β2 nAChR antagonist) had little to no
effect. C. Vesamicol and hemicholinium ablated nicotine-induced ACh production in A549 and
H358 human BACs. Each sample was analyzed in triplicate. Data represent mean + SEM from
two independent experiments. Results indicated by a different letter are significantly different (P
< 0.05).
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Figure S5. VAChT and ChAT are expressed on human BACs. ELISA assays were used to
measure the relative levels of ChAT and VAChT on A549, H358, H650 human BAC cells and
HPAEpiC normal lung cells. H520 human SCC-L cells were used as the positive control for the
assay. The absorbance obtained in H520 lysates was taken as 1 and the absorbance values in
the other cell lines were calculated as fold changes over H520. Each sample was assayed in
duplicate and the entire experiment was repeated twice. Data represent mean + SEM from two
independent experiments. Results indicated by a different letter are significantly different (P <
0.05).
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Figure S6. The transfection of VAChT-siRNA and sigma-R-siRNA suppresses the expression
of these proteins in human BACs. ELISA assays show that transfection of VAChT-siRNA-1 and
VAChT-siRNA-2 decrease the expression of VAChT in A549 cells A. and H358 cells B. Each
sample was assayed in duplicate and the entire experiment was repeated twice. Data represent
mean + SEM from two independent experiments. Results indicated by a different letter are
significantly different (P < 0.05).Western blotting experiments demonstrate that the level of
sigma-receptor is decreased after siRNA transfection in A549 cells C. and H358 cells D. The
western

blot

was

quantitated

using

NIH

ImageJ

1.46p.
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Figure S7. A. The pro-apoptotic activity of 10µM vesamicol in nicotine-treated A549 cells was
abrogated by two independent VAChT-siRNA , namely VAChT-siRNA-1 and VAChT -siRNA-2.
The transfection of a non-targeting control-siRNA had no effect on vesamicol-induced apoptosis
in A549 cells. Both the VAChT-siRNA had no effect on only nicotine-treated A549 cells (white
bars). B. The experiment was repeated in H358 human BAC cells and similar results were
obtained.

C.

The apoptotic effects of 25µM vesamicol in nicotine-treated A549 cells was

reversed by VAChT-siRNAs , namely VAChT-siRNA-1 and VAChT -siRNA-2. The VAChTsiRNAs did not have any effect on nicotine-treated A549 cells (white bars). D. The experiment
was also performed in H358 cells and similar results were obtained. E. ELISA assays show that
the transfection of both the VAChT-siRNAs caused robust suppression of VAChT levels on
A549 and H358 cells. Data represent mean + SEM from two independent experiments. Results
indicated by a different letter are significantly different (P < 0.05).
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Figure S8.

Western blot analysis shows that pcDNA3-HA-Akt-CA is overexpressed upon

transfection in A549 cells A. and H358 cells B. The transfection was performed in duplicate and
the whole experiment was repeated twice. The western blot was quantitated using NIH ImageJ
1.46p.
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